The advent of precision medicine has brought light to the treatment of non-small cell lung
cancer (NSCLC), expanding the options for patients with advanced NSCLC by targeting …

Cancer is a dynamic disease. During the course of disease, cancers generally become more
heterogeneous. As a result of this heterogeneity, the bulk tumour might include a diverse …

Context.—In 2013, an evidence-based guideline was published by the College of American
Pathologists, the International Association for the Study of Lung Cancer, and the Association …

Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …

Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …

Many effective drugs for metastatic and/or advanced-stage cancers have been developed
over the past decade, although the evolution of resistance remains the major barrier to …

Although mechanisms of acquired resistance of epidermal growth factor receptor (EGFR)-
mutant non-small-cell lung cancers to EGFR inhibitors have been identified, little is known …

Mathematical modelling approaches have become increasingly abundant in cancer
research. The complexity of cancer is well suited to quantitative approaches as it provides …

Neoplasms change over time through a process of cell-level evolution, driven by genetic
and epigenetic alterations. However, the ecology of the microenvironment of a neoplastic …

First-generation EGFR tyrosine kinase inhibitors (EGFR TKI) provide significant clinical
benefit in patients with advanced EGFR-mutant (EGFRm+) non–small cell lung cancer …